Trial Profile
Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)
Status:
Recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 28 Jan 2015
Price :
$35
*
At a glance
- Drugs Denileukin diftitox (Primary)
- Indications Cutaneous T-cell lymphoma; Peripheral T-cell lymphoma
- Focus Expanded access; Therapeutic Use
- Sponsors Eisai Inc
- 02 Sep 2014 Status changed to completed as reported by ClinicalTrials.gov record.
- 16 Sep 2011 New trial record